UNSPSC 51162322: Acetaminophen/phenylpropanolamine/phenyltoloxamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162322 Acetaminophen/phenylpropanolamine/phenyltoloxamine is a Commodity code that in recent state and local solicitations covers parenteral products, intravenous solutions, naloxone, and drug deactivation systems supplied to correctional facilities, county health departments, and emergency-response programs. State and local governments solicit under this code through corrections departments, county health agencies, and special-purpose health districts. The Washington State Department of Corrections represents the largest recent buyer, seeking parenteral nutrition solutions, IV medications, and controlled substances for incarcerated individuals across eight facilities. Work includes delivery of compounded parenteral nutrition bags within 24 hours of order, intravenous solutions within 8 hours, documented experience with patient lab monitoring and nutrition preparation, and compliance with state licensing and background-clearance requirements. Contractors must carry commercial general liability insurance of at least $1 million per occurrence, professional liability coverage of $2 million, and cyber liability protection of $2 million.

Recent activity concentrates in Washington State and Florida. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, with a response deadline of October 7, 2026, for parenteral products and services to be awarded to up to three contractors per region across West, Central, and East Washington facility groups, with contract performance running November 26, 2026 through June 30, 2030. The agency encourages small business (25%), minority-owned business (10%), women-owned business (6%), and veteran-owned business (5%) participation under Washington's Chapter 39.19 RCW. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; that procurement has a two-year initial term with one-year renewal option and compliance with E-Verify and drug-free workplace certification requirements.